Nurix Therapeutics

NRIX · NASDAQ

$26.10+$1.17 (+4.69%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $24.93

NRIX analyst rating

BuyConsensus of 13 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy13
Hold0
Underperform0
Sell0

12-month price target · 16 analysts

Average $34.92 (+33.8% upside)

Low: $25.25
Now: $26.10
High: $47.25

Upgrades and downgrades

The latest rating actions, newest first

NRIX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 16, 2026	Maintains	Buy	$34.00 → $36.00	41%
RBC Capital	Oct 13, 2026	Maintains	Outperform	$36.00 → $35.00	44%
Oppenheimer	Oct 13, 2026	Maintains	Outperform	$28.00 → $32.00	22%
Truist Securities	Oct 13, 2026	Maintains	Buy	$34.00 → $33.00	47%
Baird	Oct 13, 2026	Maintains	Outperform	$33.00 → $36.00	49%
Needham	Oct 13, 2026	Maintains	Buy	$34.00	38%
RBC Capital	Aug 10, 2026	Maintains	Outperform	$33.00 → $36.00	44%
Needham	Aug 4, 2026	Maintains	Buy	$34.00	38%
Morgan Stanley	Jul 28, 2026	Maintains	Overweight	$36.00 → $38.00	63%
UBS	Jul 22, 2026	Maintains	Buy	$23.00 → $31.00	45%

The case for and against

Updated Oct 14, 2026

Bull case

Nurix Therapeutics is favored because its lead bexobrutideg program is showing encouraging clinical efficacy and safety in CLL, supporting the view that its targeted protein degradation platform is clinically validated and potentially differentiated in B-cell malignancies and autoimmune disease. Its partnerships with Roche, SNY, GILD, and PFE add external validation, may provide non-dilutive funding, and expand the opportunity set across STAT6, IRAK4, and other pipeline assets, while the estimated ~$3B fully diluted market cap appears to reflect only about 1x potential peak bex-deg sales. Financially, F2Q26 showed a $0.81 per-share net loss, $9.0M in collaboration revenue, and about $1.14B in pro forma cash, suggesting a strong balance sheet that can support multiple upcoming clinical catalysts.

Bear case

Nurix Therapeutics is facing a negative fundamental setup because its clinical-stage value depends on a small set of unproven assets, while execution risk remains elevated across clinical trial conduct, data transparency, and management diversity. The company’s valuation framework already reflects meaningful uncertainty, assigning only a 75% probability of approval for bexobrutideg and 20% for NX-1607, and it flags the risk of negative proof-of-concept results, delayed approvals for NX-2127 and NX-5948, and possible medium- to long-term dilution. Competitive pressure in STAT6 is also intensifying, and safety concerns such as theoretical teratogenicity and possible on-target adverse effects could further constrain long-term confidence.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.